Working... Menu

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03799835
Recruitment Status : Recruiting
First Posted : January 10, 2019
Last Update Posted : April 2, 2019
Hoffmann-La Roche
Information provided by (Responsible Party):

Brief Summary:

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease.

The objective is to evaluate the efficacy of atezolizumab as measured by recurrence-free survival.

Condition or disease Intervention/treatment Phase
Bladder Cancer Drug: BCG Drug: Atezolizumab Phase 3

Detailed Description:

ALBAN study will randomize 614 patients in 30 centers in France, according to a ratio 1:1 in the following arms of treatment:

  • arm A (control arm): BCG only
  • arm B (experimental arm): BCG+ atezoliumab

The are two factors of stratifications (center and CIS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 614 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer
Actual Study Start Date : January 17, 2019
Estimated Primary Completion Date : April 1, 2022
Estimated Study Completion Date : February 1, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Active Comparator: Arm A : control arm

BCG therapy only

BCG therapy will be administered in two phases:

  • induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
  • maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).
Drug: BCG
Intravesical administration posology: 2.10⁸ - 3.10⁹ Units
Other Name: Bacillus Calmette Guerin (BCG) Medac®

Experimental: Arm B: experimental arm

BCG therapy + administration of atezolizumab

  1. BCG therapy will be administered in two phases:

    • induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)
    • maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).
  2. atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum).
Drug: BCG
Intravesical administration posology: 2.10⁸ - 3.10⁹ Units
Other Name: Bacillus Calmette Guerin (BCG) Medac®

Drug: Atezolizumab
IV perfusion
Other Names:
  • MPDL3280A
  • Tecentriq®

Primary Outcome Measures :
  1. Recurrence free survival [ Time Frame: 2 years ]
    Defined as the time from randomization to the time of first recurrence event or death. Recurrence is defined as reappearance of disease (local recurrence or occurrence of any metastasis) after the start of therapy.

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: From randomization to the date of progression, assessed up to 5 years ]
    Progression free survival defined as the time from randomization to the date of Progression defined as increase of stage from Ta to T1 or from CIS to T1; progression to MIBC (T≥ 2) or to lymph node N+ or to distant disease M+; the date of progression being determined by the endoscopic resection (TURBT) for a local relapse or by CT scan in case of non-local relapse;

  2. Disease specific survival [ Time Frame: From randomization to the date of death, assessed up to 5 years ]
    Disease-specific survival defined as the time from randomization to the date of death from bladder cancer;

  3. Overall Survival [ Time Frame: From randomization to the date of death, assessed up to 5 years ]
    Overall Survival defined as the time from randomization to the date of death from any cause

  4. Disease worsening in each arm [ Time Frame: From randomization to the date of death, assessed up to 5 years ]
    Disease worsening, defined as cystectomy or change in therapy indicative, including systemic chemotherapy or radiation therapy. The date of diagnosis (cystoscopy or CT scan) leading to cystectomy or chemotherapy will be considered as the time of disease worsening;

  5. Complete response in each arm [ Time Frame: 6 weeks and 2 years after randomization ]
    Complete response is assessed by cystoscopy and cytology.

  6. Complete response among patients with CIS [ Time Frame: 6 weeks and 2 years after randomization ]
    Complete response is assessed by cystoscopy and cytology.

  7. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 [ Time Frame: Throughout study completion, assessed up to 5 years ]
    The frequency, nature, and severity of adverse events graded according to NCI CTCAE v5.0 and according to the immune-related adverse event (irAE)

  8. Quality of life questionnaire (QLQ): QLQ-C30 questionnaire (EORTC) [ Time Frame: At randomization, every 12 weeks for years 1 and 2 after randomization, then every 24 weeks for years 3 to 5 after randomization ]

    This self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.

    The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.

    All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed informed consent form
  2. Adult man and women ( age ≥18 years)
  3. Any high risk non muscle invasive urothelial carcinoma histologically confirmed (mixed histology tumors allowed if urothelial carcinoma histology is predominant) defined on the TURBT as any of the Following :

    • T1 tumor and/or
    • High grade (G3) and/or
    • Carcinoma in situ (CIS)
  4. Tumor tissue available from the surgery for central confirmation of the diagnosis and analysis the expression of PD-L1
  5. At least one additional (second) resection of the primary tumor has been performed in case of T1 tumors, or incomplete initial TURB, or in case of doubt about completeness of a TURB, or if there is no muscle in the specimen (can be omitted if TaLG/G1 tumors or primary CIS only was found) without upstaging towards MIBC (EAU guidelines, 2017)
  6. Absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan of the pelvis, abdomen, and chest no more than 42 days prior to the first study treatment
  7. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  8. Life expectancy ≥12 weeks
  9. Systolic blood pressure (BP) <160 mmHg and diastolic BP <95 mmHg, as documented within 7 days prior to the first study treatment (hypertension allowed provided it is controlled)
  10. Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 7 days prior to the first study treatment:

    • absolute neutrophil count (ANC) ≥1500 cells/μL
    • white blood cell (WBC) counts >2500/μL
    • Lymphocyte count ≥300/μL
    • Platelet count ≥100,000/μL
    • Hemoglobin ≥9.0 g/dL
    • aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), and alkaline phosphatase ≤2.5 × the upper limit of normal (ULN)
    • Serum bilirubin ≤1.0 × ULN Patients with known Gilbert disease who have serum bilirubin level ≤3 × ULN may be enrolled.
    • Partial thromboplastin time (PTT)/Prothrombin Time (PT) ≤1.5 × ULN or international normalized ratio (INR) <1.7 × ULN
    • Calculated creatinine clearance ≥20 mL/min (Cockcroft-Gault formula)
  11. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab
  12. Patients affiliated to the social security system
  13. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

  1. Patient having received previous BCG therapy for bladder cancer
  2. Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment. Hormone-replacement therapy or oral contraceptives are authorized
  3. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug, whichever is longer, prior to day 1 of study treatment
  4. Malignancies other than urothelial cancer within 5 years prior to Day 1 of cycle 1 of treatment except the following:

    • Patients with localized low risk prostate cancer (defined as Stage ≤T2b, Gleason score ≤7, and PSA at prostate cancer diagnosis ≤20 ng/mL [if measured]) treated with curative intent and without prostate-specific antigen (PSA) recurrence are eligible.
    • Patients with low risk prostate cancer (defined as Stage T1/T2a, Gleason score ≤7 and PSA ≤10 ng/mL) who are treatment-naive and undergoing active surveillance are eligible.
    • Patients with malignancies of a negligible risk of metastasis or death (e.g., risk of metastasis or death <5% at 5 years) are eligible provided they meet all of the following criteria: malignancy treated with expected curative intent (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) and no evidence of recurrence or metastasis by follow-up imaging and any disease-specific tumor markers.
  5. Pregnancy or breastfeeding
  6. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  7. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  8. History of autoimmune disease or history of immunosuppression, or conditions associated with congenital or acquired immune deficiency , including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix 6 for a more comprehensive list of autoimmune diseases)

    • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.
    • Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
    • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan may be eligible.
    • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  9. Serum albumin <2.5 g/dL
  10. Known HIV infection
  11. Patients with known active hepatitis B virus (HBV; chronic or acute; defined as having a positive hepatitis B surface antigen (HBsAg) test at screening) or hepatitis C.

    • Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody (HBc Ab) and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to randomisation.
    • Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  12. Known active tuberculosis
  13. Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
  14. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
  15. Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1 Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.
  16. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.

    - Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction <50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  17. Major surgical procedure other than for diagnosis within 4 weeks prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study
  18. Prior allogeneic stem cell or solid organ transplant
  19. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation if such a live, attenuated vaccine will be required during the study

    - Influenza vaccination should be given during influenza season only (approximately October through May in the Northern Hemisphere and approximately April through September in the Southern Hemisphere). Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Cycle 1, Day 1, at randomization, during treatment or within 5 months following the last dose of atezolizumab (for patients randomized to atezolizumab).

  20. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
  21. Prior treatment with CD137 agonists or immune checkpoint−blockade therapies, including anti-CD40, anti−CTLA-4, anti−PD-1, and anti−PD-L1 therapeutic antibodies
  22. Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin 2 (IL-2)) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
  23. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor (anti-TNF) agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial

    • Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea, multiple doses for contrast allergy) may be enrolled in the study.
    • The use of inhaled or low-dose (e.g., ≤10 mg/day prednisone) corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) and low-dose corticosteroids for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  24. Person deprived of their liberty or under protective custody or guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03799835

Layout table for location contacts
Contact: Soazig Nénan-Le Ficher +33185343113
Contact: Maggy Chausson +33185343112 ext +33185343112

Layout table for location information
Hôpital G. Montpied Not yet recruiting
Clermont-Ferrand, France, 63003
Contact: Laurent Guy, MD         
Contact: Sébastien Bailly, MD         
Clinique Claude Bernard Not yet recruiting
Ermont, France, 95120
Contact: Laurent Thomas, MD         
Contact: Julie Giroud, MD         
CHU Grenoble Not yet recruiting
Grenoble, France, 38043
Contact: Jean-Luc Descotes, MD-PHD         
Contact: Mathieu Laramas, MD         
Hôpital privé Toulon - Sainte Marguerite Active, not recruiting
Hyères, France, 83400
Hôpital privé de la Louvière Not yet recruiting
Lille, France, 59800
Contact: Pierre Colin, MD         
Contact: Olvier Romano, MD         
Insitut Paoli Calmette Recruiting
Marseille, France, 13009
Contact: Géraldine Pignot, MD         
Contact: Gwenaelle Gravis, MD         
Hôpital européen Georges Pompidou Active, not recruiting
Paris, France, 75010
Hôpital Saint Louis Not yet recruiting
Paris, France, 75010
Contact: Alexandra Masson-Lecomte, MD         
Contact: Hélène Gautier, MD         
Institut Mutualiste Montsouris Recruiting
Paris, France, 75014
Contact: Rafael Sanchez-Salas, MD         
Contact: Mostefa Bennamoun, MD         
Hôpital Diaconesses- Croix Saint Simon Recruiting
Paris, France, 75020
Contact: Philippe Sebe, MD         
Contact: Camille Serrate, MD         
Hôpital La Pitié Salpétrière Recruiting
Paris, France, 75651
Contact: Morgan Roupret, MD-PHD         
Contact: Aurélien Gobert, MD         
Hôpitaux d'instruction des armées Begin Recruiting
Saint-Mandé, France, 94160
Contact: Xaiver Durand, MD         
Contact: François-Régis Ferrand, MD-PHD         
Hôpital Foch Active, not recruiting
Suresnes, France, 92150
Hôpitaux Leman Active, not recruiting
Thonon-les-Bains, France, 74200
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Morgan Roupret, MD-PHD Hôpital Pitié-Salpétrière
Principal Investigator: Yohann Loriot, MD Gustave ROUSSY

Layout table for additonal information
Responsible Party: UNICANCER Identifier: NCT03799835     History of Changes
Other Study ID Numbers: UC-0160/1717
First Posted: January 10, 2019    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Antibodies, Monoclonal
BCG Vaccine
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic